Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis
Gilmar Reis, MD, PhD* ,*,
Mauro S. Motta, MD,
Marcia M. Barbosa, MD, PhD* ,
William A. Esteves, MD ,
Sonia F. Souza, MD and
Edimar A. Bocchi, MD, PhD||
* Cardiovascular Research Program, Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Brazil
Cardiologica, Clinica de Diagnostico Cardiovascular, Belo Horizonte, Brazil
Ecocenter, Vera Cruz and Socor Hospitals, Belo Horizonte, Brazil
Division of Cardiology, Vera Cruz Hospital, Belo Horizonte, Brazil
|| Heart Institute–University of Sao Paulo Medical School, Sao Paulo, Brazil
View larger version (22K):
[in a new window]
|
Figure 1 Correlation between mean diastolic mitral valve (MV) gradient (mm Hg) and MV flow (ml/s) in 53 patients with rheumatic mitral stenosis and clinical events (dashed lines) and in patients without clinical events (solid lines). Data were obtained at rest and during peak dobutamine stress echocardiography.
|
|
View larger version (18K):
[in a new window]
|
Figure 2 Sensitivity, specificity, and accuracy of dobutamine stress echocardiography (DSE) for prediction of clinical events during follow-up of patients with rheumatic mitral stenosis (variable adopted: DSE-mean diastolic mitral valve gradient).
|
|
View larger version (16K):
[in a new window]
|
Figure 3 Kaplan-Meier product-moment event rates in patients with mitral stenosis. The cut-off point (18 mm Hg) was derived from the obtained performance of the test according to the presence or absence of clinical events during follow-up.
|
|
|
